Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Andrew R. Allen
AddedMar 31, 2024
UpdatedMay 31, 2026
Andrew R. Allen

Andrew R. Allen

Board Member, Gritstone bio

CrunchbaseLinkedIn

Andrew R. Allen's Career

Gritstone bio
Gritstone bio

Emeryville, CA, US

Board Member· Board
Revitope Oncology
Revitope Oncology

San Francisco, CA, US

Board Member· Board
Verge Genomics
Verge Genomics

San Francisco, CA, US

Board Member· Board
Nodality
Nodality

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Andrew R. Allen's Career

Gritstone bio
Gritstone bio

Emeryville, CA, US

Board Member· Board
Revitope Oncology
Revitope Oncology
Series A$8.5M322014San Francisco, CA, US
Board Member· Board

Leadership at Revitope Oncology

Mark CobboldMark CobboldBoard Member
David MillarDavid MillarCo-Founder
Carsten ReinhardtCarsten ReinhardtBoard Member
Andrew AllenAndrew AllenCo-Founder
Lou LangeLou LangeBoard Member
Steve ArkinstallSteve ArkinstallCEO
Verge Genomics
Verge Genomics
Series B$134.1M832015San Francisco, CA, US
Board Member· Board

Leadership at Verge Genomics

Mario SaltarelliMario SaltarelliBoard Member
Emily MeltonEmily MeltonBoard Member
Gwen MelincoffGwen MelincoffBoard Member
Alice ZhangAlice ZhangFounder & CEO
Alfred SandrockAlfred SandrockBoard Member
Jason ChenJason ChenCo-Founder
Nodality
Nodality
Series B$62M752003South San Francisco, CA, US
Board Member· Board

Leadership at Nodality

Garry NolanGarry NolanBoard Member
Michael GoldbergMichael GoldbergBoard Member
Omar PerezOmar PerezFounder
Laura BregeLaura BregeCEO
Greg CritchfieldGreg CritchfieldBoard Member
David SingerDavid SingerBoard Member

Similar to Nodality

NormunityNormunityWest Haven, CT, USCancer Treatmentsest. 2021NormunityWest Haven, CT, US · est. 2021

Normunity: A biotech firm innovating precision immuno-oncology medicines to boost body's cancer immunity.

Series A · $65M15
Nuon TherapeuticsNuon TherapeuticsSan Mateo, CA, USTherapiesest. 2002Nuon TherapeuticsSan Mateo, CA, US · est. 2002

Nuon Therapeutics: A US-based biotech firm innovating therapies for autoimmune and inflammatory diseases.

Series A · $48M75

Andrew R. Allen's Similar Executives & Operators

Bo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoMason YeoMason YeoBoard Member · KakaoSean JohSean JohBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · Kakao

People Similar to Andrew R. Allen

Elaine V. JonesElaine V. JonesBoard Member · NextCureNataly ShtraizentNataly ShtraizentFounder · Grit BioJustin SampsonJustin SampsonCo-Founder · GRIT.Alan LewisAlan LewisBoard Member · Batu Biologics